FINNEY ELISHA W sold $69K of ICUI

FINNEY ELISHA W sold 378 shares of ICU MEDICAL INC/DE (ICUI) at $182.48 on 2026-08-11.

Original reporting
SEC EDGAR · FINNEY ELISHA W
Published Aug 11, 2026, 9:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ICUI
Neutral
low confidence
Mentioned
$ICUI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

Insider selling can be interpreted as caution, but without additional disclosures (earnings, guidance, litigation, or operational changes) it is usually not a strong standalone trading catalyst.

02

Market read

Traders may briefly reassess sentiment around ICUI due to the director sale, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The transaction size is modest relative to typical institutional flows, and the article lacks context on total holdings, prior sales cadence, or reasons for the sale.

Relevance 3/10Novelty 3/10Timing: filed on 2026-08-11 (after-hours)

Background

The article is an SEC Form 4 insider transaction disclosure for ICU Medical, Inc. (ICUI).

Company-level read

Ticker impact

$ICUINeutralLow confidence
Context

ICU Medical director Elisha W Finney filed a Form 4 selling 378 shares at $182.4818 on 2026-08-11, totaling about $68,978.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small, non-10b5-1 sale by a director, but the article provides no accompanying fundamental change, guidance, or enforcement context.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity or diversification, and the absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • ICU Medical, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Elisha W. Finney

    Director who sold 378 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIHighAI 8/10

ICU Medical (ICUI) Q3 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q3 2026 adjusted EPS of $2.44, up 20% YoY, with adjusted EBITDA at $114M. Revenue growth was driven by consumables (+5%) and IV systems (+11%), while Vital Care declined (-10%). The company expects full-year EBITDA and EPS to be at the higher end of previous guidance.

$ICUIMedAI 8/10

ICU Medical Inc (ICUI) Q3 2026 Earnings Call Highlights: Record Sales, 20% EPS Growth

ICU Medical Inc reported Q3 2026 earnings with 11% growth in Infusion Systems, driven by competitive wins and customer utilization. The company aims for a 43% gross margin by 2027, with potential for earlier achievement. FDA requested additional testing for MedFusion 5,000 syringe pump and ambulatory pump submissions. Management discussed macroeconomic challenges, currency impacts, and strategic initiatives like the Otsuka joint venture.

$ICUIHigh

ICU Medical Q3 Earnings Call Highlights

ICU Medical (ICUI) reported Q3 earnings, noting delayed Infusion Systems volume and revised growth expectations. Vital Care revenue declined 12% due to logistics issues, with full-year decline expected to be larger than anticipated. Adjusted gross margin expanded to 42%, with debt reduction continuing. The company maintained 2026 guidance but lowered capital spending forecasts.

$ICUIHighAI 8/10

ICU Medical: Q3 Earnings Snapshot

ICU Medical Inc. (ICUI) reported Q3 net income of $26.8M, or $1.07 per share, beating estimates. Adjusted EPS was $2.44, and revenue was $560.4M, also exceeding forecasts. The company expects full-year EPS of $8.60-$9.00.